Aktienanalyse zu Tyra Biosciences Inc (TYRA)TYRATyra Biosciences Inc

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tyra Biosciences is not a good buy right now due to its declining stock performance and negative financial indicators. The current price is $18.52, which is significantly below the analyst price targets, with Oppenheimer's target at $40. However, the stock has seen a 30.87% decline year-to-date and a 28.02% drop over the last 20 days, indicating weakness. Additionally, the RSI is at a low 24.3, suggesting oversold conditions, but this does not guarantee a rebound. The main risk is the ongoing negative earnings trend, with projected losses increasing to -$45.56 million in Q2 2026, which could further erode investor confidence.